Biocardia Stock Performance

BCDA -  USA Stock  

USD 1.55  0.14  8.28%

The firm shows a Beta (market volatility) of 1.5101, which signifies a somewhat significant risk relative to the market. Let's try to break down what Biocardia's beta means in this case. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Biocardia will likely underperform. Even though it is essential to pay attention to Biocardia historical returns, it is always good to be careful when utilizing equity current trending patterns. Our philosophy towards foreseeing any stock's future performance is to check both, its past performance charts as well as the business as a whole, including all available technical indicators. Biocardia exposes twenty-eight different technical indicators, which can help you to evaluate its performance. Biocardia has an expected return of -0.31%. Please be advised to confirm Biocardia maximum drawdown, semi variance, and the relationship between the sortino ratio and potential upside to decide if Biocardia performance from the past will be repeated at some point in the near future.
  
Refresh
Biocardia Performance
0 of 100
Over the last 90 days Biocardia has generated negative risk-adjusted returns adding no value to investors with long positions. Despite fragile performance in the last few months, the Stock's fundamental indicators remain somewhat strong which may send shares a bit higher in June 2022. The current disturbance may also be a sign of long term up-swing for the company investors. ...more

Biocardia Price Channel

Quick Ratio3.51
Fifty Two Week Low1.1000
Target High Price15.00
Fifty Two Week High5.1000
Target Low Price3.00

Biocardia Relative Risk vs. Return Landscape

If you would invest  209.00  in Biocardia on February 23, 2022 and sell it today you would lose (54.00)  from holding Biocardia or give up 25.84% of portfolio value over 90 days. Biocardia is currently does not generate positive expected returns and assumes 5.599% risk (volatility on return distribution) over the 90 days horizon. In different words, 48% of stocks are less volatile than Biocardia, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon.
 Daily Expected Return (%) 
      Risk (%) 
Given the investment horizon of 90 days Biocardia is expected to under-perform the market. In addition to that, the company is 4.07 times more volatile than its market benchmark. It trades about -0.06 of its total potential returns per unit of risk. The DOW is currently generating roughly -0.06 per unit of volatility.

Biocardia Market Risk Analysis

Today, many novice investors tend to focus exclusively on investment returns with little concern for Biocardia's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Biocardia, and traders can use it to determine the average amount a Biocardia's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.

Sharpe Ratio = -0.055

Best
Portfolio
Best
Equity
Good Returns
Average Returns
Small Returns
CashSmall
Risk
Average
Risk
High
Risk
Huge
Risk
Negative ReturnsBCDA
Estimated Market Risk
 5.6
  actual daily
 
 48 %
of total potential
 
4848
Expected Return
 -0.31
  actual daily
 
 0 %
of total potential
 
00
Risk-Adjusted Return
 -0.05
  actual daily
 
 0 %
of total potential
 
00
Based on monthly moving average Biocardia is performing at about 0% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Biocardia by adding it to a well-diversified portfolio.

About Biocardia Performance

To evaluate Biocardia Stock as a possible investment, you need to clearly understand its upside potential, downside risk, and overall future performance outlook. You may be satisfied when Biocardia generates a 15% return over the last few months, but what if the market is generating 25% over the same period? In this case, it makes sense to compare Biocardia Stock's performance with different market indexes, such as the Dow or NASDAQ Composite. These indexes can act as benchmarks that will help you to understand Biocardia stock market performance in a much more refined way. At Macroaxis, we take it even further. The Macroaxis performance score is an integer between 0 and 100 that represents Biocardia's market performance from a risk-adjusted return perspective. Generally speaking, the higher the score, the better is overall performance as compared to other investors. The score is normalized against the average investing universe (the best we can interpret from the data available). Within this methodology, scores of individual equity instruments will always be inferior to the scores of portfolios of equities as portfolios typically diversify a lot of unsystematic risks away. The formula to derive the Macroaxis score bases on multiple unequally-weighted factors. For more information, refer to our portfolio performance evaluation section.
Please also refer to our technical analysis and fundamental analysis pages.
Last ReportedProjected for 2022
Return on Average Assets(0.66) (0.71) 
Return on Average Equity(0.87) (0.94) 
Return on Invested Capital 7.96  8.18 
Return on Sales(12.44) (12.76) 
BioCardia, Inc., a clinical-stage regenerative medicine company, develops cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases. In addition, it offers the Helix biotherapeutic delivery system that delivers therapeutics into the heart muscle with a penetrating helical needle from within the heart and Morph deflectable guides and sheaths. Biocardia operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 28 people.

Things to note about Biocardia

Checking the ongoing alerts about Biocardia for important developments is a great way to find new opportunities for your next move. Our stock alerts and notifications screener for Biocardia help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.

Biocardia Alerts

Equity Alerts and Improvement Suggestions

Biocardia generated a negative expected return over the last 90 days
Biocardia has high historical volatility and very poor performance
Biocardia may become a speculative penny stock
The company reported the previous year's revenue of 1.01 M. Net Loss for the year was (12.62 M) with loss before overhead, payroll, taxes, and interest of (7.54 M).
Biocardia currently holds about 12.87 M in cash with (10.37 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.76.
Biocardia has a frail financial position based on the latest SEC disclosures
Roughly 31.0% of the company shares are held by company insiders
Latest headline from MacroaxisInsider: Payment of 20632 shares by David McClung of Biocardia subject to Rule 16b-3
Continue to Trending Equities. Note that the Biocardia information on this page should be used as a complementary analysis to other Biocardia's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Global Correlations module to find global opportunities by holding instruments from different markets.

Complementary Tools for Biocardia Stock analysis

When running Biocardia price analysis, check to measure Biocardia's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Biocardia is operating at the current time. Most of Biocardia's value examination focuses on studying past and present price action to predict the probability of Biocardia's future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Biocardia's price. Additionally, you may evaluate how the addition of Biocardia to your portfolios can decrease your overall portfolio volatility.
Pair Correlation
Compare performance and examine fundamental relationship between any two equity instruments
Go
Stock Screener
Find equities using custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook.
Go
Sync Your Broker
Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors.
Go
Fund Screener
Find actively-traded funds from around the world traded on over 30 global exchanges
Go
Portfolio Center
All portfolio management and optimization tools to improve performance of your portfolios
Go
Bollinger Bands
Use Bollinger Bands indicator to analyze target price for a given investing horizon
Go
Volatility Analysis
Get historical volatility and risk analysis based on latest market data
Go
Theme Ratings
Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance
Go
Idea Breakdown
Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes
Go
Companies Directory
Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals
Go
Portfolio File Import
Quickly import all of your third-party portfolios from your local drive in csv format
Go
Is Biocardia's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Biocardia. If investors know Biocardia will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Biocardia listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Biocardia is measured differently than its book value, which is the value of Biocardia that is recorded on the company's balance sheet. Investors also form their own opinion of Biocardia's value that differs from its market value or its book value, called intrinsic value, which is Biocardia's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Biocardia's market value can be influenced by many factors that don't directly affect Biocardia's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Biocardia's value and its price as these two are different measures arrived at by different means. Investors typically determine Biocardia value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Biocardia's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.